Alembic Pharmaceuticals Limited

rs,

: 3rd February, 2025 To, The Manager, Department of Corporate Services, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 533573 To, The Manager, Listing Department,

4%

d failure to gain market acceptance. Quarterly Snapshot INR Bn Key Highlights : Revenue 16.93 4% YoY 3% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23%

3%

e to gain market acceptance. Quarterly Snapshot INR Bn Key Highlights : Revenue 16.93 4% YoY 3% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -1

7%

rket acceptance. Quarterly Snapshot INR Bn Key Highlights : Revenue 16.93 4% YoY 3% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -10% QoQ Net

1%

y Snapshot INR Bn Key Highlights : Revenue 16.93 4% YoY 3% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -10% QoQ Net Profit Margin 8.2% India

5%

ot INR Bn Key Highlights : Revenue 16.93 4% YoY 3% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -10% QoQ Net Profit Margin 8.2% India Branded

16%

ghts : Revenue 16.93 4% YoY 3% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -10% QoQ Net Profit Margin 8.2% India Branded Business : India Brande

23%

4% YoY 3% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -10% QoQ Net Profit Margin 8.2% India Branded Business : India Branded Business recorded 3%

10%

% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -10% QoQ Net Profit Margin 8.2% India Branded Business : India Branded Business recorded 3% growth wi

8.2%

DTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -10% QoQ Net Profit Margin 8.2% India Branded Business : India Branded Business recorded 3% growth with topline of INR 6.14 billi

INR 6.14 billion

it Margin 8.2% India Branded Business : India Branded Business recorded 3% growth with topline of INR 6.14 billion for Q3 FY25. US Generics : Growth of 10% on YoY basis is driven by ramp up of the key launches a

11%

5.21 2.99 2.59 16.93 5.96 4.74 2.72 2.89 16.31 3% 10% 10% -10% 4% 6.09 4.67 2.98 2.74 16.48 1% 11% 1% -5% 3% 17.95 14.49 8.68 7.91 49.02 16.97 13.08 7.90 9.16 47.12 Geographical Sales – 9M FY25

“Revenue 16.93 4% YoY 3% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -10% QoQ Net Profit Margin 8.2% India Branded Business : India Branded Business recorded 3% growth with topline of INR 6.14 billion for Q3 FY25.”

“Product registrations and dossier extensions to new markets are on track to accelerate growth.”

“Anticipate good growth in coming quarters backed by decent order book.”

“Q3 FY25 Growth Comparison Therapy Gynaecology Anti Diabetic Ophthalmology Dermatology APL 7% 15% 12% 13% Market* 5% 17% 13% 15% *Above market growth are based on respective Molecule group Source: IQVIA Qtr Dec-24 New Launches New launches continue to do well along with promising future launches across key segments.”

“➢5+ expected product launches in Q4 FY25.”

“Ex-US Business Revenue – Q3 FY25 INR Bn Revenue – Last 5 years 2.72 Growth 10% 2.99 CAGR: 21% INR Bn 10.52 Q3FY24 Q3FY25 ➢Growth of 10% driven by high demand across the markets.”

“7.79 7.75 8.52 4.97 ➢Future growth will be fueled by new launches and territory expansions.”

“FY20 FY21 FY22 FY23 FY24 API Business Revenue – Q3 FY25 2.89 De-Growth (-10%) 2.59 INR Bn Revenue – Last 5 years CAGR: 15% 11.66 INR Bn 12.46 Q3FY24 Q3FY25 ➢Decline of 10% on YoY basis, on account of the pricing headwinds and low off–take from few selected customers.”

“➢Expect steady growth for this business.”

Key Highlights

1

Targets

1

Investor Relations Advisors

1

Key Highlights

Revenue 16.93 4% YoY 3% QoQ R&D 7% of Sales EBIDTA 2.71 1% YoY 5% QoQ EBIDTA Margin 16% Net Profit 1.38 -23% YoY -10% QoQ Net Profit Margin 8.2% India Branded Business : India Branded Business recorded 3% growth with topline of INR 6.14 billion for Q3 FY25. US Generics : Growth of 10% on YoY basis is driven by ramp up of the key launches and market share gain in few existing products. New launches to drive growth in coming quarter. Ex-US Generics : Momentum continued for Q3 as well with a 10% growth on YoY basis. Demand outlook remains strong. Product registrations and dossier extensions to new markets are on track to accelerate growth. API : Decline of 10% on YoY basis, on account of low off-take from few selected customers and the pricing headwinds. Anticipate good growth in coming quarters backed by decent order book. Revenue Snapshot Business Formulations India US Ex-US API Total Revenue Q3 FY25 Q3 FY24 Y-o-Y Q2 FY25 Q-o-Q 9M FY25 9M FY24 Y-o-Y INR Bn 6.14 5.21 2.99 2.59 16.93 5.96

Targets

➢ Net-Zero by 2040 ➢ Water Neutrality by 2027 ➢ Plant 50,000 trees by 2027 ▪ API-Unit-2 has been bestowed with the Safety Merit Award” “International organized by the British Safety Council for its to good health and safety dedication management and best practices, for year 2024 • Alembic has been awarded with Silver Award in recently concluded Times Now Global Sustainability Alliance SDG Summit 2024 for Best Climate Action Project Strategic Roadmap Business Initiatives in FY24 Plan for FY25 The India Business The US Generics Business The RoW Generics Business • • • • • • • • • • Ipads for MR interaction with the Increased focus on the animal health space with therapy leading products. Deployment of Healthcare Medical Professional’s (HMP’s) Upgraded to SalesForce platform for India field force to get better control, consistency in execution and drive better orientation towards HMP’s. Commercial operations ramped up from new facilities backed by product launches and Market share gain La

Investor Relations Advisors

Adfactors PR Pvt. Ltd. Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactorspr.com